Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi® (crofelemer) in the OnTarget study's prespecified ...
Miami Herald5 天
Jaguar Health Meeting with FDA Regarding Results of Phase 3 OnTarget Study
The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 ...
Jaguar Health’s Napo granted FDA Type C Meeting to discuss OnTarget study
Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has granted Napo a Type C Meeting in the second quarter of 2025 to ...